Calcium channel blockers: indications and limitations 2. Use in angina and other cardiac disorders.
As discussed in part 1 of this article (page 97), intravenous verapamil (Calan, Isoptin) has established antiarrhythmic value. Attention now centers, however, on the antianginal value of the calcium channel blocking drugs because of the recent introduction of oral preparations for control of variant, stable and unstable angina.
D000284:Administration, Oral; D000787:Angina Pectoris / Q000188:drug therapy*; D000788:Angina Pectoris, Variant / Q000188:drug therapy; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D006332:Cardiomegaly / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D007275:Injections, Intravenous; D009203:Myocardial Infarction / Q000188:drug therapy; D011897:Random Allocation; D014700:Verapamil / Q000008:administration & dosage
D002121:Calcium Channel Blockers; D014700:Verapamil